All N = 175 (100%) | Left BC group N = 84 (48%) | Right BC group N = 91 (52%) | p value | ||
---|---|---|---|---|---|
58 (49–64) | 59 (52–67) | 55 (46–63) | 0.0096 | ||
Premenopause | 90 (51.4%) | 38 (45.2%) | 52 (57.1%) | 0.155 | |
Pomenopause | 85 (48.5%) | 46 (54.8%) | 39 (42.9%) | ||
Ductal invasive | 168 (96%) | 81 (96.4%) | 87 (95.6%) | 1 | |
Lobular invasive | 4 (2.3%) | 2 (2.4%) | 2 (2.2%) | ||
Other | 3 (1.7%) | 1 (1.2%) | 2 (2.2%) | ||
G 1 | 2 (1.1%) | 0 | 2 (2.2%) | 0.337 | |
G 2 | 48 (27.4%) | 21 (25%) | 27 (29.7%) | ||
G 3 | 125 (71.5%) | 63 (75%) | 62 (68.1%) | ||
ER positive | 97 (55.4%) | 53 (63%) | 44 (48.3%) | 0.851 | |
PR positive | 82 (46.8%) | 43 (51.2%) | 39 (42.8%) | ||
ER in PR negative | 73 (41.7%) | 28 (33.3%) | 45 (49.4%) | ||
Smoking | 33 (19%) | 13 (15%) | 20 (22%) | 0.365 | |
Arterial hypertension | 35 (20%) | 21 (25%) | 14 (15.4%) | 0.161 | |
Diabetes | 3 (1.7%) | 3 (3.4%) | 0 | 0.108 | |
Hyperlipidemia | 30 (17.1%) | 16 (19%) | 14 (15.4%) | 0,658 | |
Known heart disease All diseases had been already present at diagnosis of breast cancer. Group 1: mild aortic stenosis; Group 2: mitral valve prolapse; compensated hypertonic heart and symptomatic angina pectoris; undefined cardiomyopathy |
4 (2.3%) | 1 (1.2%) | 3 (3.3%) | 0.621 |
All (N = 175) (%) | Left BC Group (N = 84) (%) | Right BC Group (N = 91) (%) | P value | |
---|---|---|---|---|
Cumulative dose- mg/m2 BSA | ||||
(Median [Q1–Q3]) | 350 (292–499) | 352 (295–497) | 349 (290–499) | 0.799 |
Cumulative dose- mg/m2 BSA | 297 | 297 | 298 | 0.783 |
(Median [Q1–Q3]) | (276–594) | (281–422) | (273–768) | |
Cumulative dose- mg/m2 BSA | 2316 | 2344 | 2268 | 0.482 |
(Median [Q1–Q3]) | (1758–2924) | (1763–2992) | (1758–2829) | |
AC/EC/FAC/FEC + taxanes | 95 (54.3%) | 40 (47.6%) | 55 (60.4%) | 0.235 |
AC/EC/FAC/FEC without taxanes | 69 (39.4%) | 38 (45.3%) | 31 (34.1%) | |
Other | 11 (6.3%) | 6 (7.1%) | 5 (5.5%) | |
Tamoxifen | 39 (22.3%) | 21 (25%) | 18 (19.8%) | 0.652 |
Aromatase inhibitor | 45 (25.7%) | 26 (30.9%) | 19 (20.8%) | |
Other | 10 (5.7%) | 7 (8.3%) | 3 (3.3%) | |
Cumulative dose- mg/kg BSA | 105 (97–114) | 105 (97–116) | 105 (97–112) | 0.658 |
(Median [Q1–Q3]) | ||||
Mastectomy | 91 (52%) | 38 (45.2%) | 53 (58.2%) | 0.116 |
Breast conserving surgery | 84 (48%) | 46 (54.8) | 38 (41.8%) |
All (N = 175) | Left BC Group (N = 84) | Right BC Group (N = 91) | P value | |
---|---|---|---|---|
65 (60–69) | 65 (61–70) | 63 (59.5–67) | 0.0208 | |
(Median [Q1–Q3]) | ||||
66 (62–70) | 67 (64–70) | 65 (60–70.5) | 0.117 | |
(Median [Q1–Q3]) | ||||
(n = 149) | (n = 70) | (n = 79) | 0.562 | |
LVEF0 (%)-LVEF1(%) = Δ LVEF | -2.22 (8.69) | -1.78 (7.85) | -2.60 (9.4) | 95% CI: -2.004 – 3.648 |
(Mean [SD]) |
Left BC Group (n = 84) (median [Q1–Q3]) | Right BC Group (n = 91) (median [Q1–Q3]) | p value | |
---|---|---|---|
4.6 (4.4–4.9) | 4.6 (4.4–4.8) | 0.913 | |
95% CI (-0.10-0.10) | |||
2.9 (2.6–3.1) | 2.8 (2.5–3.2) | 0.541 | |
95% CI (-0.19–0.10) | |||
3.4 (3.2–3.8) | 3.4 (3.2–3.7) | 0.830 | |
95% CI (-0.10–0.10) | |||
4.4 (4.0–4.8) | 4.5 (4.2–4.6) | 0.979 | |
95% CI (-0.10–0.10) | |||
3.2 (3.0–3.6) | 3.4 (3.0–3.7) | 0.298 | |
95% CI (-0.20–0.00) | |||
4.1 (3.8–4.4) | 4.3 (3.9–4.4) | 0.226 | |
95% CI (-2.0–3.00) | |||
68.5 (64–74.2) | 68.0 (63.0–72.5) | 0.758 | |
95% CI (-2.0–3.00) | |||
1.07 (0.80–1.23) | 1.08 (0.87–1.32) | 0.113 | |
95% CI (-0.18–0.02) | |||
7.15 (6.27–9.26) | 7.40 (6.18–8.68) | 0.918 | |
95% CI (-0.52–0.66) | |||
1.368 (1.065–1.600) | 1.149 (0.94–1.35) | 0.002 | |
95% CI ( 0.07–0.29) | |||
8.0 (7.0–9.1) | 8.0 (7.0–9.1) | 0.985 | |
95% CI (-0.50–0.50) | |||
10.0 (7.82–11.37) | 10.0 (8.05–11.8) | 0.547 | |
95% CI (-0.10–0.50) |
All (N = 175) (%) | Left BC group (N = 84) (%) | Right BC group (N = 91) (%) | p value | |
---|---|---|---|---|
parasternal lymph nodes were not included in the irradiated area |
||||
Breast | 70 (40%) | 38 (45.3%) | 32 (35.2%) | 0.434 |
Breast + scl | 17 (9.7%) | 9 (10.7%) | 8 (8.8%) | |
Thoracic wall | 17 (9.7%) | 8 (9.5%) | 9 (9.9%) | |
Thoracic wall + scl | 71 (40.6%) | 29 (34.5%) | 42 (46.1%) | |
2D RT | 139 (79.4%) | 69 (82.1%) | 70 (76.9%) | 0.256 |
3D CRT | 25 (14.3%) | 12 (14.3%) | 13 (14.3%) | |
Electrons +/- photons | 11 (6.3%) | 3 (3.6%) | 8 (8.8%) | |
25 × 2 Gy | 14 (84.6%) | 73 (86.9%) | 75 (82.4%) | 0.540 |
17 or 18 × 2.5 Gy | 27 (15.4%) | 11 (13.1%) | 16 (17.6%) |
ECHO | All (N = 174) (%) | Left BC Group (N = 83) (%) | Right BC Group (N = 91) (%) | p value | |
---|---|---|---|---|---|
Pericard | Normal | 164 (94.3%) | 74 (89%) | 90 (99%) | 0.007 |
Effusion | 10 (5.7%) | 9 (11%) | 1 (1%) |